Cargando…
Pharmacological chaperone therapy for Fabry disease
Fabry disease is an inherited lysosomal storage disorder caused by deficient α-galactosidase A activity. Many missense mutations in Fabry disease often cause misfolded gene products, which leads to their retention in the endoplasmic reticulum by the quality control system; they are then removed by e...
Autor principal: | ISHII, Satoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japan Academy
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278969/ https://www.ncbi.nlm.nih.gov/pubmed/22241068 http://dx.doi.org/10.2183/pjab.88.18 |
Ejemplares similares
-
Chaperone Therapy in Fabry Disease
por: Weidemann, Frank, et al.
Publicado: (2022) -
Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests
por: Andreotti, Giuseppina, et al.
Publicado: (2011) -
A thermodynamic assay to test pharmacological chaperones for Fabry disease()
por: Andreotti, Giuseppina, et al.
Publicado: (2014) -
Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
por: Cammisa, Marco, et al.
Publicado: (2013) -
Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease
por: Lukas, Jan, et al.
Publicado: (2020)